Allostery at opioid receptors: modulation with small molecule ligands
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Opioid receptors are 7‐transmembrane domain receptors that couple to heterotrimeric G proteins. The endogenous ligands for opioid receptors are peptides which bind to the orthosteric site on the receptors. The μ‐opioid receptor is the target for opioid analgesics, while the δ‐opioid receptor has been suggested as a target for pain management, migraine and depression. Similarly, κ‐opioid receptors are involved in pain and depression and nociceptin receptors in pain and mood behaviours. However, exogenous orthosteric ligands for opioid receptors cause a myriad of on‐target side effects. Recently, selective allosteric ligands for μ‐ and δ‐opioid receptors have been described. These compounds bind to a site on the receptor distinct from the orthosteric site. Occupation of this allosteric site leads to modulation of orthosteric ligand binding affinity and/or efficacy. Allosteric modulators may be positive, negative or silent (neutral) (PAMs, NAMs or SAMs respectively). PAMs may have in vivo activity by enhancing the activity of exogenous drugs or endogenous opioid peptides. Enhancing endogenous opioid peptide activity maintains the temporal and spatial distribution of these molecules but improves, and potentially qualitatively changes, activity at their cognate receptors which could limit side effects compared with traditional opioid drugs. In this review, we describe the rationale and promise for the development of allosteric modulators for opioid receptors, the discovery of selective allosteric modulators, the identification of potential allosteric sites on opioid receptors and the mode of action of the modulators. Linked Articles: This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722 · cited 1×
“However, while activation of μ-receptors provides pain relief, it also results in a wide range of unwanted effects including constipation and life-threatening respiratory depression, as well as rewarding effects that lead to addiction liability (Matthes et al., 1996).”
BackgroundAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 2×
“For example, the βarrestin pathway has been implicated in the constipatory and respiratory depressive actions of opioids (Raehal and Bohn, 2011), and newly developed biased ligands including oliceridine (TRV130; Dewire et al., 2013) and PZM21 (Manglik et al.”
BackgroundDifferential binding properties of oripavines at cloned μ- and δ-opioid receptors
Lee, K. O., Akil, H., Woods, J. H., & Traynor, J. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00460-4 · Cited by 117
Self-citationFawzi, A. B., Macdonald, D., Benbow, L. L., Smith-Torhan, A., Zhang, H., Weig, B. C., Ho, G., Tulshian, D., Linder, M. E., & Graziano, M. P. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12353-x · Cited by 82 · cited 1×
“Finally, a thiazolidine compound, SCH-202676 (Figure 2), has been claimed to be a non-specific allosteric modulator of many GPCRs including the μ-, δ- and κ-receptors (Fawzi et al., 2001).”
BackgroundLewandowicz, A. M., Vepsäläinen, J., & Laitinen, J. T. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706624 · Cited by 34 · cited 1×
“However, this compound covalently binds to GPCRs by sulfhydryl bond formation and so is not a true allosteric modulator (Göblyös et al., 2005; Lewandowicz et al., 2006).”
Background
Cited by
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Mu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
“Compounds such as BU72 have been described as potential MOR superagonists because of their ability to induce a stable conformational state.(42,43) This suggests the possibility that the basis of the superagonism shown by the nitazenes may come from the induction of a unique and stable conformational state able to robu…”
BackgroundAlhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17376 · Cited by 23
“Alternatively, some fentanyls and nitazenes may act both at the orthosteric site as agonists and at an allosteric site to reduce the affinity of naloxone binding (Livingston & Traynor, 2018; O'Brien et al., 2024).”
Metadata
- Authors
- Livingston, K. E., & Traynor, J. R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-06-07
- Volume
- 175
- Issue
- 14
- Pages
- 2846-2856
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2606908569
- Cited by
- 134
- References
- 7
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.